Staff Publications

Staff Publications

  • external user (warningwarning)
  • Log in as
  • language uk
  • About

    'Staff publications' is the digital repository of Wageningen University & Research

    'Staff publications' contains references to publications authored by Wageningen University staff from 1976 onward.

    Publications authored by the staff of the Research Institutes are available from 1995 onwards.

    Full text documents are added when available. The database is updated daily and currently holds about 240,000 items, of which 72,000 in open access.

    We have a manual that explains all the features 

Record number 417586
Title A highly conserved neutralizing epitope on group 2 influenza A viruses
Author(s) Ekiert, D.C.; Friesen, R.H.E.; Bhanha, G.; Kwaks, T.; Jongeneelen, M.; Yu, W.; Ophorst, C.; Cox, F.; Korse, H.J.W.M.; Brandenburg, B.; Vogels, R.; Brakenhoff, J.P.J.; Kompier, R.; Koldijk, M.H.; Cornelissen, A.H.M.; Poon, L.L.M.; Peiris, M.; Koudstaal, W.; Wilson, I.A.; Goudsmit, J.
Source Science 333 (2011)6044. - ISSN 0036-8075 - p. 843 - 850.
Department(s) CVI Virology
Publication type Refereed Article in a scientific journal
Publication year 2011
Keyword(s) monoclonal-antibodies - avian influenza - hemagglutinin - fusion - ph - recognition - vaccination - subtypes - peptide - season
Abstract Current flu vaccines provide only limited coverage against seasonal strains of influenza viruses. The identification of VH1-69 antibodies that broadly neutralize almost all influenza A group 1 viruses constituted a breakthrough in the influenza field. Here, we report the isolation and characterization of a human monoclonal antibody CR8020 with broad neutralizing activity against most group 2 viruses, including H3N2 and H7N7, which cause severe human infection. The crystal structure of Fab CR8020 with the 1968 pandemic H3 hemagglutinin (HA) reveals a highly conserved epitope in the HA stalk distinct from the epitope recognized by the VH1-69 group 1 antibodies. Thus, a cocktail of two antibodies may be sufficient to neutralize most influenza A subtypes and, hence, enable development of a universal flu vaccine and broad-spectrum antibody therapies
There are no comments yet. You can post the first one!
Post a comment
Please log in to use this service. Login as Wageningen University & Research user or guest user in upper right hand corner of this page.